|Application ||WB, IHC-P, FC, E|
|Calculated MW||61874 Da|
|Antigen Region||14-42 aa|
|Other Names||Bridging integrator 2, Breast cancer-associated protein 1, BIN2, BRAP1|
|Target/Specificity||This BIN2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 14-42 amino acids from the N-terminal region of human BIN2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Precautions||BIN2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Promotes cell motility and migration, probably via its interaction with the cell membrane and with podosome proteins that mediate interaction with the cytoskeleton. Modulates membrane curvature and mediates membrane tubulation. Plays a role in podosome formation. Inhibits phagocytosis.|
|Cellular Location||Cytoplasm. Cell projection, podosome membrane; Peripheral membrane protein; Cytoplasmic side Cytoplasm, cell cortex. Cell projection, phagocytic cup Note=Associates with membranes enriched in phosphoinositides Detected in the actin-rich cell cortex at the leading edge of migrating cells. Detected at podosomes, at an actin-rich ring-like structure|
|Tissue Location||Detected in natural killer cells (at protein level). Highest level expression seen in spleen and peripheral blood leukocytes and is also expressed at high levels in thymus, colon and placenta, suggesting preferential expression in hematopoietic tissues.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Scherer, S.E., et al. Nature 440(7082):346-351(2006)
Ge, K., et al. Genomics 67(2):210-220(2000)
If you have any additional inquiries please email technical services at email@example.com.